Alembic Pharmaceuticals has announced the appointment of G Krishnan as its new Chief Financial Officer (CFO).

Krishnan brings over two decades of leadership experience in finance and allied functions across the pharmaceutical, life sciences, telecom, and social sectors.

Before joining Alembic, Krishnan served as Vice President at Syngene International Ltd.—a global contract research, development, and manufacturing organisation—since May 2020.

His career also includes senior positions at Tata Trusts, Vodafone, and Reliance Industries.

A qualified Chartered Accountant (ACA), Cost and Management Accountant, and Company Secretary, Krishnan’s core strengths lie in developing and executing financial strategies, leading corporate development initiatives such as M&A and IPOs, providing decision support and performance benchmarking across business units, and managing investor relations to communicate the company’s equity story.

“We are pleased to welcome Mr. G Krishnan as Chief Financial Officer at Alembic Pharmaceuticals. We are confident that his expertise will be instrumental in Alembic’s next phase of growth,” the company shared in an official post on its LinkedIn account.

Krishnan succeeds R. K. Baheti, who has stepped down from the CFO role. Baheti will, however, continue to serve as Executive Director of the company, in line with the terms of his appointment.

Expressing his enthusiasm for the new role, Krishnan said, “Alembic’s legacy of over 100+ years in innovation and healthcare, its strong values, and its growth mindset deeply resonates with me. As I step into this new role, I carry forward the invaluable learnings from my time at Syngene International Limited —an institution that shaped me in many ways. My heartfelt thanks to all my colleagues, mentors, and friends who’ve supported me along the journey.”

This leadership change comes shortly after Alembic Pharmaceuticals strengthened its U.S. presence through the strategic acquisition of Utility Therapeutics via its U.S. subsidiary, Alembic Pharmaceuticals Inc.

With this move, the company is preparing to launch Pivya, an FDA-approved treatment for uncomplicated urinary tract infections, across the U.S. market.